DIARY: Flu drug bugs hacks as PR lips all seem sealed

PR Week found itself going round in circles when following up the story that the National Institute of Clinical Excellence (NICE) wouldn’t recommend Glaxo Wellcome’s Relenza as an NHS drug.

PR Week found itself going round in circles when following up the

story that the National Institute of Clinical Excellence (NICE) wouldn’t

recommend Glaxo Wellcome’s Relenza as an NHS drug.



On calling Hill and Knowlton, which handles Relenza for Glaxo Wellcome,

I was assured an expert on the matter would call me back.



Unfortunately, the ’expert’ was not allowed to comment, and instead

directed me to Glaxo Wellcome communications manager Phil Thomson, who

would comment.



A similar call to NICE was, however, a little sad. ’We don’t have a

press office,’ I was told. It emerged that all media enquiries were

being ably dealt with by new communications director, Anne Toni Rodgers,

who unfortunately has yet to appoint a PR team.



Things being the way they are in the public sector, Rodgers is unlikely

to see any new staff joining before this current media deluge is

over.



Maybe any spare bods at H&K, not allowed to comment on Relenza by

Wellcome, might like to volunteer their services in the interim.



Would you like to post a comment?

Please Sign in or register.

News by email...